Lexaria Bioscience Corp. announced on November 25, 2024, that dosing has been completed for human pilot study #3. This study investigated a DehydraTECH-processed version of tirzepatide, the active ingredient in Zepbound®, in an oral dose format.
The study successfully dosed nine healthy volunteers, marking the conclusion of the active administration phase. This milestone allows the company to proceed with data collection and analysis.
Completing dosing is a crucial step towards generating results on the tolerability and efficacy of oral DehydraTECH-tirzepatide. The findings from this study are anticipated to inform future clinical development.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.